ESSENTIEL ( à partir de aout 2025)
Food supplement declared in France, decision dated 29 May 2025
ESSENTIEL ( à partir de aout 2025) (UNAE) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Ascophyllum nodosum 230.8 mg per day, Tagetes erecta 100 mg per day, Styphnolobium japonicum 51.02 mg per day, Crocus sativus 30 mg per day, Brassica nigra 15.8 mg per day. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- UNAE
- Food business operator placing the product on the market
- LES PATTES DOUCES SAS
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 4 gélules
- Directions for use
- Prendre 4 gélules par jour
- Intended populations
- Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking anticoagulants, Taking antidepressants, Taking thyroid medication
Declaration 270941, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Ascophyllum nodosum (L.) Le Jolis | Thalle | Autre extrait sec | 230.8 mg |
| Tagetes erecta L. | Fleur | Extrait sec aqueux | 100 mg |
| Styphnolobium japonicum (L.) Schott | Bourgeon | Extrait sec hydroalcoolique | 51.02 mg |
| Crocus sativus L. | Stigmates | Extrait sec hydroalcoolique | 30 mg |
| Brassica nigra (L.) K.Koch | Graine | Extrait sec aqueux | 15.8 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Fibres solubles d'acacia | not declared |
| Acétylcystéine | not declared |
| Ubiquinone | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| (6S)-5-methyltetrahydrofolic acid, glucosamine salt | Folate (vitamin B9) | 1,000 µg | 200 µg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| thiamin hydrochloride | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| methylcobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| riboflavin | Vitamin B2 (riboflavin) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
| mixed tocopherols | Vitamin E | 300 mg | 30 mg |
| menaquinone | Vitamin K | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| zinc bisglycinate | Zinc | 25 mg | 15 mg |
Additives
E1204
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne peuvent être utilisés comme substituts d’un régime alimentaire varié et équilibré et d’un mode de vie sain. Tenir hors de portée des enfants. A conserver dans un endroit frais et sec. Déconseillé aux enfants, aux femmes enceintes et allaitantes, aux personnes sous traitement anticoagulant de la famille des antivitamines K, aux personnes sous antidépresseurs, aux personnes souffrant de troubles de la thyroïde, aux personnes allergiques à la moutarde.
Regulatory points
- Conditions légales
Brassica nigra (L.) K.Koch: L'huile essentielle de cette plante est interdite.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Acétylcystéine
Read the warning, when it applies and the studies cited
N-ACETYL-L-CYSTEINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).
Sources cited by Health Canada (2)
- Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
- Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed
Contraindications
Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).
Sources cited by Health Canada (4)
- Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomised trial
- Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Review article
- Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
- Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : UNAE
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “ESSENTIEL ( à partir de aout 2025) (UNAE): composition and regulation”, https://compoatlas.com/en/supplements/products/270941-essentiel-a-partir-de-aout-2025, updated 15 November 2026.